14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
LXRX vs RGNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, REGENXBIO Inc. (RGNX) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin).
Growth vs. Quality Trade-Off: RGNX earns the overall head-to-head edge with a stronger Unified Composite Score (45.3/100 HOLD vs. LXRX 38.7/100 SELL) and 1.82β · 76% Vol risk profile, whereas LXRX leads top-line expansion (-20.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment55.9% of Rev ($86M)
90D Engineering Disclosures0 Published
Investor FAQ LXRX vs RGNX Key Questions & Quantitative Answers
As of Nov 16, 2026, REGENXBIO Inc. (RGNX) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin). Growth vs. Quality Trade-Off: RGNX earns the overall head-to-head edge with a stronger Unified Composite Score (45.3/100 HOLD vs. LXRX 38.7/100 SELL) and 1.82β · 76% Vol risk profile, whereas LXRX leads top-line expansion (-20.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LXRX leads the Growth & Scale pillar: LXRX posts -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LXRX cumulative revenue shifted +66.7% while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, LXRX deploys N/A (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.
RGNX screens cheaper on headline valuation multiples. LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 21.3x EV/Revenue (unreported FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LXRX (-43.9% ROE) versus RGNX (-113.2% ROE) capital efficiency.
In options market volatility and institutional positioning, LXRX carries 78.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.63β · 60% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.